Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data

IMPORTANCE: Quantitative assessment of bias from unmeasured confounding and missing data can help evaluate uncertainty in findings from indirect comparisons using real-world data (RWD). OBJECTIVE: To compare the effectiveness of alectinib vs ceritinib in terms of overall survival (OS) in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkinson, Samantha, Gupta, Alind, Scheuer, Nicolas, Mackay, Eric, Arora, Paul, Thorlund, Kristian, Wasiak, Radek, Ray, Joshua, Ramagopalan, Sreeram, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498851/
https://www.ncbi.nlm.nih.gov/pubmed/34618040
http://dx.doi.org/10.1001/jamanetworkopen.2021.26306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498851/
https://www.ncbi.nlm.nih.gov/pubmed/34618040
http://dx.doi.org/10.1001/jamanetworkopen.2021.26306

Ejemplares similares